Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT Plus Vitamin D3 for High-grade Anal Dysplasia and Microinvasive Anal Cancer
NCT02698293Phase 1Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of 5-aminolevulinic acid and vitamin d in anal dysplasia and carcinoma in situ (CIS) (3 cohorts), sponsored by Abramson Cancer Center. Primary endpoint: Number of adverse events at 18 months. Planned start Dec 2019; status: withdrawn.
02
Drugs
5-aminolevulinic acidvitamin d
03
Conditions
anal dysplasiacarcinoma in situ (CIS)
Beyond the preview
Go deeper on NCT02698293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698293.